1. Guerra L, Dellambra E, Brescia S, Raskovic D. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab. 2010. 11:451–467.
Article
2. Boone B, Ongenae K, Van Geel N, Vernijns S, De Keyser S, Naeyaert JM. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol. 2007. 17:55–61.
3. Seirafi H, Farnaghi F, Firooz A, Vasheghani-Farahani A, Alirezaie NS, Dowlati Y. Pimecrolimus cream in repigmentation of vitiligo. Dermatology. 2007. 214:253–259.
Article
4. Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology. 2003. 207:322–323.
Article
5. Sendur N, Karaman G, Saniç N, Savk E. Topical pimecrolimus: a new horizon for vitiligo treatment? J Dermatolog Treat. 2006. 17:338–342.
Article
6. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol. 2005. 15:88–91.
7. Farajzadeh S, Daraei Z, Esfandiarpour I, Hosseini SH. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol. 2009. 26:286–291.
Article
8. Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges. 2006. 4:942–946.
Article
9. Choi CW, Chang SE, Bak H, Choi JH, Park HS, Huh CH, et al. Topical immunomodulators are effective for treatment of vitiligo. J Dermatol. 2008. 35:503–507.
Article
10. Köse O, Arca E, Kurumlu Z. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat. 2010. 21:133–139.
Article
11. Khalid M, Mujtaba G. Response of segmental vitiligo to 0.05% clobetasol propionate cream. Int J Dermatol. 1998. 37:705–708.
Article
12. Kang HY, Choi YM. FK506 increases pigmentation and migration of human melanocytes. Br J Dermatol. 2006. 155:1037–1040.
Article
13. Lan CC, Wu CS, Chen GS, Yu HS. FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. Br J Dermatol. 2011. 164:490–496.
Article
14. Lan CC, Kao YH, Huang SM, Yu HS, Chen GS. FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. Br J Dermatol. 2004. 151:679–684.
Article
15. Lubaki LJ, Ghanem G, Vereecken P, Fouty E, Benammar L, Vadoud-Seyedi J, et al. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. Arch Dermatol Res. 2010. 302:131–137.
Article